Abstract
Because of the fading immunity to COVID-19 and continuous evolution of the SARS-CoV-2 Omicron variants, the next epidemic wave of COVID-19 is inevitable. The Omicron variant has been the cause of several waves of the COVID-19 epidemics in the majority of countries. Thus, lessons from other countries may provide guidance regarding the timing and magnitude of the next COVID-19 wave of the pandemic in China. In this study, the COVID-19 surveillance data from 189 countries that experienced two or more waves of the SARS-CoV-2 Omicron variant were analysed. The median peak timing between the first and second/third waves of the SARS-CoV-2 Omicron variant was 164/243 days. The peaks of the second and third waves were much lower than that of the first wave. The median relative peaks of the second and third compared with the first waves were 14.5% and 11.2%, respectively. The time window between the peak timings of the first and second waves showed no significant rank correlation with the five socioeconomic factors included in this study. However, the relative peak of the second wave increased significantly with gross domestic product per capita (P<0.001), urbanisation rate (P=0.003), population density (P=0.007), and proportion of older adults >65 years (P<0.001), although decreased significantly with the proportion of 0-14 teenagers (P<0.001). In summary, the historical situations and progression of COVID-19 outbreaks in other countries may inform the risk assessment of incoming outbreaks in mainland China; however, the timing and magnitude of the next COVID-19 wave may also be influenced by several unknown factors, including rapid viral evaluation of SARS-CoV-2
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by grants from the National Natural Science Foundation of China (Grant No. 82003509 to H.L.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used (or will use) ONLY openly available human data that were originally located at:WHO Coronavirus (COVID-19) Dashboard(https://covid19.who.int), Johns Hopkins University Center for Systems Science and Engineering (https://coronavirus.jhu.edu/map.html), and Our World in Data (https://ourworldindata.org/covid-vaccinations).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at:WHO Coronavirus (COVID-19) Dashboard(https://covid19.who.int), Johns Hopkins University Center for Systems Science and Engineering (https://coronavirus.jhu.edu/map.html), and Our World in Data (https://ourworldindata.org/covid-vaccinations).
